NCT02239627

Brief Summary

Low back pain is a common condition, affecting majority of the adults in the United States at some point in their lives. Fortunately, most resolve, even without treatment. However, some suffer from continued or recurrent pain. For those suffering from continued or recurrent low back pain, numerous treatment options exist. One such option is an epidural injection, particularly when other non-surgical treatment options have failed. An epidural injection is the placement of a needle into the space around the spinal cord with the aid of a live X-Ray machine, followed by an injection of various medications. Typically, the medication that is injected is a steroid, commonly with the combination of local anesthetic medication. Epidural steroid injections, with or without local anesthetic is part of the established standard of care in the United States for those with continued or recurrent low back pain. The steroid is believed to reduce inflammation and edema of the injured or irritated nerves. However, despite the routine use of epidural steroids, the steroid itself is not without risks or side effects. Though rare, the steroids have been associated with complications including osteoporosis, steroid induced myopathy, cataracts and many others. In order to minimize the side effects associated with epidural steroids, limiting the dose and frequency have been outlined. Clonidine is another medication, commonly used in numerous clinical settings. U. S. Food and Drug Administration approved the medication for epidural use for cancer pain but studies have shown effectiveness in non-cancer pain was well and is routinely used for various conditions. There is growing evidence on the use of epidural clonidine for treatment of pain, including low back pain. This research will study and compare the effectiveness, if any, of clonidine compared to steroid in an epidural injection for low back pain.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

September 10, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 15, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
5.6 years until next milestone

Results Posted

Study results publicly available

January 20, 2021

Completed
Last Updated

January 20, 2021

Status Verified

December 1, 2020

Enrollment Period

9 months

First QC Date

September 10, 2014

Results QC Date

December 22, 2020

Last Update Submit

December 22, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain Intensity Measured on Visual Analog Scale (VAS)

    3 months

Secondary Outcomes (3)

  • Percentage of Pain Relief

    Day 0, 3 weeks, 3 months

  • Level of Disability (Oswestry Back Scale)

    3 weeks, 3 months

  • Adverse Events

    Day 0, 3 weeks, 3 months

Study Arms (2)

Steroid

ACTIVE COMPARATOR

Epidural steroid injection

Drug: Epidural steroid

Clonidine

EXPERIMENTAL

Epidural clonidine injection

Drug: Clonidine

Interventions

Steroid
Clonidine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has clinical diagnosis of low back due to intervertebral disc disease, spinal stenosis or herniated disc
  • Subject has average pain score (VAS) at least 5
  • Subject has persistent pain despite conservative care
  • Subjects has experienced pain for at least 1 month
  • years of age or older when written informed consent is obtained
  • Signed Institutional Review Board (IRB) approved informed consent form

You may not qualify if:

  • Allergy to clonidine, dexamethasone, ropivicaine or lidocaine
  • Coagulopathy
  • Active Infection
  • Serious neurologic deficit
  • Subject is pregnant or planning on becoming pregnant during the course of the study
  • Subject is member of a vulnerable population
  • Investigator suspects substance abuse that might confound the study results
  • Subject has unresolved major issues of secondary gain (as determined by the investigator)
  • Subject exhibits major psychiatric morbidity, untreated or refractory to treatment as determined by the investigator
  • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West Virginia University Hospitals

Morgantown, West Virginia, 26505, United States

Location

MeSH Terms

Conditions

Back Pain

Interventions

Clonidine

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Clinical Trials Compliance Coordinator
Organization
West Virginia Universtiy, WVCTSI

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2014

First Posted

September 15, 2014

Study Start

September 1, 2014

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

January 20, 2021

Results First Posted

January 20, 2021

Record last verified: 2020-12

Locations